BioMarin Pharmaceutical (NASDAQ: BMRN) insider transactions

In the twelve months to 10 November 2026, executives and directors of BioMarin Pharmaceutical reported 5 open-market sales of 69,711 shares ($4.3m) and 0 open-market purchases, by 3 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in BioMarin Pharmaceutical shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
30 September 2026	Friberg Gregory R	EVP, Chief R&D Officer	Shares withheld for tax	−4,086	$60.00	47,732	Form 4
10 September 2026	Plenge Robert M	Director	Grant or award	+6,140	—	6,140	Form 4
2 September 2026	Davis George Eric	EVP, Chief Legal Officer	Open-market sale	−17,557	$66.28	61,003	Form 4
2 June 2026	Anderson Elizabeth M	Director	Grant or award	+7,490	—	41,940	Form 4
2 June 2026	Bodem Barbara W.	Director	Grant or award	+7,490	—	21,045	Form 4
2 June 2026	Clark Ian T	Director	Grant or award	+7,490	—	14,490	Form 4
2 June 2026	Dere Willard H	Director	Grant or award	+7,490	—	46,440	Form 4
2 June 2026	Enyedy Mark J	Director	Grant or award	+7,490	—	21,040	Form 4
2 June 2026	Hombach Robert J.	Director	Grant or award	+7,490	—	49,360	Form 4
2 June 2026	Ho Maykin	Director	Grant or award	+7,490	—	35,500	Form 4
2 June 2026	Walbert Timothy P	Director	Grant or award	+7,490	—	17,270	Form 4
2 June 2026	Countouriotis Athena	Director	Grant or award	+7,490	—	21,040	Form 4
20 May 2026	Hubbard Cristin	EVP, Chief Commercial Officer	Shares withheld for tax	−2,318	$50.20	42,472	Form 4
7 May 2026	Friberg Gregory R	EVP, Chief R&D Officer	Open-market sale	−3,281	$53.85	51,818	Form 4
18 March 2026	Davis George Eric	EVP, Chief Legal Officer	Shares withheld for tax	−1,273	$56.05	78,560	Form 4
17 March 2026	Hardy Alexander	Chief Executive Officer	Shares withheld for tax	−4,252	$56.05	214,635	Form 4
17 March 2026	Mueller Brian	EVP, Chief Financial Officer	Shares withheld for tax	−2,117	$56.05	123,314	Form 4
17 March 2026	Guyer Charles Greg	EVP, Chief Technical Officer	Shares withheld for tax	−1,693	$56.05	84,140	Form 4
17 March 2026	Friberg Gregory R	EVP, Chief R&D Officer	Shares withheld for tax	−1,629	$56.05	55,099	Form 4
17 March 2026	Hubbard Cristin	EVP, Chief Commercial Officer	Shares withheld for tax	−1,245	$56.05	44,790	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the BioMarin Pharmaceutical page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.